Use of amelotex to treat patients with acute musculoskeletal pain in the back and grade 1 essential hypertension

Abstract

Among nonsteroidal anti-inflammatory drugs, meloxicam has a slight effect on blood pressure (BP). Objective: to study the efficacy and safety of amelotex in acute musculoskeletal pain in the lumbosacral region and essential hypertension (EH). Subjects and methods. An open-label comparative trial of the safety and efficacy of amelotex (meloxicam injectable dosage form) in an intramuscular dose of 15 mg/day and diclofenac sodium in an intramuscular dose of 75 mg/day was conducted in 120 patients with acute muscu- loskeletal pain in the lumbosacral region and grade 1 EH. Results. Amelotex was as effective as diclofenac sodium in reducing the intensity of pain and the degree of vertebral syndrome and decreasing the restricted daily activity of patients with acute lumbalgia and concomitant grade 1 EH. Ten-day use of amelotex in the above dose caused no significant BL elevation. Conclusion. Amelotex was observed to be highly effective and well tolerated in patients with grade 1 EH who were treated for acute muscu- loskeletal pain in the back.

Keywords

• meloxicam
• diclofenac
• nonsteroidal anti-inflammatory drugs
• back pain
• essential hypertension